ENHANCING THE ANTI-TUMOR IMMUNITY AND THERAPEUTIC POTENTIAL OF ICT01, A BUTYROPHILIN3A-TARGETED, gamma 9 delta 2 T CELL-ACTIVATING MONOCLONAL ANTIBODY, WITH LOW DOSE IL-2 IN PATIENTS WITH ADVANCED SOLID TUMORS: THE EVICTION-2 TRIAL - Aix-Marseille Université Accéder directement au contenu
Article Dans Une Revue JOURNAL FOR IMMUNOTHERAPY OF CANCER Année : 2022

ENHANCING THE ANTI-TUMOR IMMUNITY AND THERAPEUTIC POTENTIAL OF ICT01, A BUTYROPHILIN3A-TARGETED, gamma 9 delta 2 T CELL-ACTIVATING MONOCLONAL ANTIBODY, WITH LOW DOSE IL-2 IN PATIENTS WITH ADVANCED SOLID TUMORS: THE EVICTION-2 TRIAL

Dates et versions

hal-04084962 , version 1 (28-04-2023)

Identifiants

Citer

Johann de Bono, Stephane Champiat, Francois-Xavier Danlos, Martin Wermke, Volker Kunzmann, et al.. ENHANCING THE ANTI-TUMOR IMMUNITY AND THERAPEUTIC POTENTIAL OF ICT01, A BUTYROPHILIN3A-TARGETED, gamma 9 delta 2 T CELL-ACTIVATING MONOCLONAL ANTIBODY, WITH LOW DOSE IL-2 IN PATIENTS WITH ADVANCED SOLID TUMORS: THE EVICTION-2 TRIAL. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (2), pp.A753. ⟨10.1136/jitc-2022-SITC2022.0720⟩. ⟨hal-04084962⟩
8 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More